Photo via Toronto Star

A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning

Read the original at Toronto Star ↗
Cite

Neergaard, L. (2026, October 22). A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning. Toronto Star. https://www.thestar.com/news/world/a-novel-mrna-cancer-vaccine-helps-reduce-the-chances-of-melanoma-patients-tumors-returning/article_8e605465-f902-5f18-8209-5c5b35973f7b.html

Dated from the outlet's own feed. Check the original for its byline.

Toronto Star · collected 2026-10-22 · by Lauran Neergaard

Quick Summary

Moderna and Merck released results from a major study showing that an mRNA-based cancer vaccine called intismeran significantly reduces by 42% the risk of melanoma returning two years after surgery. The personalized vaccine, which targets unique gene mutations in each patient's tumor, was administered alongside standard post-surgery treatment to over 1,100 people with high-risk melanoma. At the end of the trial, 82% of patients receiving the vaccine remained cancer-free compared to 70% in the control group.
Written by AI on 2026-10-23, from this article's own text only (the story summary below draws on all the coverage).
See how they differ ↓

AI analysis

Story summary

Moderna and MSD developed intismeran, a personalized mRNA-based vaccine, which when combined with Keytruda (pembrolizumab) reduced the risk of melanoma recurrence or death by 42% in patients two years after surgery. The trial included over 1,100 participants with high-risk melanoma that had been surgically removed. Intismeran targets up to 34 tumor neoantigens specific to each patient's tumor, enhancing the immune system’s ability to fight cancer. Although results are promising and could mark a turning point in personalized cancer treatment, longer-term studies are needed to confirm long-term benefits and impact on overall survival rates. The vaccine is currently experimental and not available on healthcare systems like NHS yet. Similar approaches are being tested for other cancers including kidney, bladder, and lung cancer. The detailed findings were initially scheduled to be presented at the European Society of Medical Oncology Congress but were released ahead of time due to data leaks. Lead researcher Professor Georgina Long from Melanoma Institute Australia described the results as "phenomenal" and potentially transformational for cancer treatment. Independent experts also view the outcome positively, though they emphasize the need for extended follow-up studies to establish definitive benefits in patient longevity.

Written for “mRNA Cancer Vaccine Breakthrough For Melanoma” on 2026-11-21, grounded in this article and the 7 other(s) covering the same event.

How they differ

8 outlets covered “mRNA Cancer Vaccine Breakthrough For Melanoma”.

What each outlet says

One AI summary per outlet of its latest article on this story, written from that article alone and checked against it. Open the article for the outlet's own words.

Toronto StarThis outlet22 Oct

Moderna and Merck released results from a major study showing that an mRNA-based cancer vaccine called intismeran significantly reduces by 42% the risk of melanoma returning two years after surgery. The personalized vaccine, which targets unique gene mutations in each patient's tumor, was administered alongside standard post-surgery treatment to over 1,100 people with high-risk melanoma. At the end of the trial, 82%…

A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning (this article)
The Independent22 Oct

ModernA’s mRNA cancer vaccine combined with Merck's immunotherapy reduced melanoma recurrence or death risk by 42%, according to a Phase 3 clinical trial involving over 1,100 patients. The study also showed a 38% reduction in the spread of cancer and revealed that 82.2% of patients receiving both treatments remained cancer-free after two years compared to 70% for those treated with Keytruda alone. ModernA plans to…

mRNA cancer vaccine slashes melanoma death or recurrence risk by 42% →
Time23 Oct

Moderna and Merck announced on October 22 that their customized cancer vaccine for late-stage melanoma reduces recurrence or death risk by 42% over two years compared to standard treatment. The study involved more than 1,130 patients who had tumors surgically removed and were then given either the intismeran vaccine (along with Keytruda) or a placebo plus Keytruda. Intismeran uses mRNA technology to help immune…

A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42% →
Daily Mail23 Oct

Professor Georgina Long led a world-first cancer vaccine trial that significantly reduced the risk of melanoma recurrence or death by 42% compared to patients treated with only pembrolizumab (Keytruda). The study, involving 1,137 participants across 157 global sites, tested an individualised mRNA vaccine called intismeran, developed by Moderna and MSD. This breakthrough could revolutionize cancer treatment…

World-first cancer vaccine slashes death risk in stunning findings led by Aussie scientist →
ABC News (AU)23 Oct

Researchers led by Australia have developed a world-first cancer vaccine that significantly reduces the risk of melanoma recurrence by 42 percent, according to phase 3 trial results. The study, set to be published in the New England Journal of Medicine, involved 1,137 patients and compared personalized mRNA-based vaccines combined with immunotherapy against immunotherapy alone. The treatment identifies unique…

Australia at the heart of 'transformational' cancer vaccine breakthrough →
BBC23 Oct

A new personalized cancer vaccine, when combined with an existing immunotherapy drug called Keytruda, has shown significant promise in reducing the recurrence and spread of melanoma by 42% and 38%, respectively, over two years. This trial involved more than 1,100 patients who had their tumors surgically removed. The vaccine, named Intismeran, uses mRNA technology similar to that used in some COVID vaccines, tailored…

First personalised cancer vaccine cuts risk of disease returning in major trial →
Show 2 more outlets
Evening Standard23 Oct

A large trial has shown that a personalized mRNA cancer vaccine for melanoma reduces the risk of recurrence or death by 42% when used with immunotherapy. The study involved over 1,100 high-risk melanoma patients who had surgery to remove their tumors. This vaccine works by targeting specific markers on each patient’s tumor and activating an immune response against these unique cancer mutations. The combination…

World’s first mRNA cancer jab for melanoma cuts risk of death by 42% →
CBC23 Oct

Moderna and Merck released results from a major study showing their mRNA-based personalized cancer vaccine, intismeran, significantly reduces the risk of melanoma recurrence by 42% when used in conjunction with an existing treatment. The vaccine is tailored to each patient based on unique genetic mutations found in their tumor, leveraging mRNA technology similar to that used in COVID-19 vaccines. Dr. Hussein Tawbi…

A novel mRNA cancer vaccine helps cut the chances of melanoma tumor recurrence in major study →

Where they agree and split

Framing

How the first headlines put it

Stated as fact7
The headlines (7)

mRNA cancer vaccine slashes melanoma death or recurrence risk by 42% The Independent · stated as fact

A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning Toronto Star · stated as fact

A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42% Time · stated as fact

World-first cancer vaccine slashes death risk in stunning findings led by Aussie scientist Daily Mail · stated as fact

Australia at the heart of 'transformational' cancer vaccine breakthrough ABC News (Australia) · stated as fact

First personalised cancer vaccine cuts risk of disease returning in major trial BBC · stated as fact

World’s first mRNA cancer jab for melanoma cuts risk of death by 42% Evening Standard · stated as fact

The full story: what happened, how it changed, and all 8 articles →

Compared with similar articles

This article reads unscored and hedges 9% of its claims. Each row says how that neighbour differs.
CBC News
Hedges 3 of 46 claims Outlet record 72/100
The Independent
Hedges 0 of 16 claims Outlet record 59/100
ABC News (AU)
Hedges 3 of 34 claims Outlet record 67/100
TIME
Hedges 3 of 28 claims Outlet record 60/100
Daily Mail
Hedges 1 of 10 claims Outlet record 69/100
BBC News
Hedges 2 of 28 claims Outlet record 65/100
Evening Standard
Hedges 1 of 25 claims Outlet record 64/100

Story

mRNA Cancer Vaccine Breakthrough For Melanoma
Health · 8 article(s) covering the same event. Compare every outlet's account →
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
35
sentences that state something as happening or true
Uncertain
9%
3 of 35 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
65/100
Toronto Star's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
8
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-10-23 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

Toronto Star · 16516 article(s) · 32 correction(s) detected
Running correction rate · 32 correction(s)
2026-11-17
Correction
2026-10-26
Correction
2026-10-24
Correction
2026-10-07
Correction
2026-09-24
Correction

Who wrote this

Lauran Neergaard
8 article(s) here · 1 carrying a prediction
But because people with mild symptoms may not be diagnosed, the new study in Belo Horizonte, Brazil, went further.
An extra hour of sleep is on the way for most Americans, though the “fall back” to standard time will bring darker afternoons, too.
"It's a big step forward for science, for oncology, because this vaccine will apply to many different cancers," said Dr. Michael Atkins, deputy director of Georgetown University's Lombardi Comprehensive Cancer Center.
“It’s a big step forward for science, for oncology, because this vaccine will apply to many different cancers,” said Dr. Michael Atkins, deputy director of Georgetown University’s Lombardi Comprehensive Cancer Center.
The shot-averse could choose a nasal spray, FluMist, if they're ages 2 to 49 and meet other health criteria.
The shot-averse could choose a nasal spray, FluMist, if they’re ages 2 to 49 and meet other health criteria.
Also by Lauran Neergaard
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 8 articles by Lauran Neergaard →

Topics

Houston MD Anderson Cancer Center Merck Moderna WASHINGTON

Subjects

Merck ORG · 4× Moderna ORG · 4× Houston GPE · 2× Georgetown University’s ORG · 1× Hussein Tawbi PERSON · 1× Karen Knudsen PERSON · 1× MD Anderson Cancer Center ORG · 1× Michael Atkins PERSON · 1× WASHINGTON GPE · 1× the Parker Institute ORG · 1×

Narrative

Moderna and Merck had announced in August that the late-stage trial of intismeran was successful but the detailed results were set to be released Saturday at a meeting of the European Society of Medical Oncology in Madrid.
framing: assertive · carried by 1 article(s) · first seen 2026-10-23
“It’s a big step forward for science, for oncology, because this vaccine will apply to many different cancers,” said Dr. Michael Atkins, deputy director of Georgetown University’s Lombardi Comprehensive Cancer Center.

Claims (35 extracted, 3 hedged)

A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients’ tumors come back, according to results of a major study released Thursday by drugmakers Moderna and Merck. uncertain
tumors → reduce → Moderna
The vaccine was custom-brewed for each patient to match their tumor. asserted
vaccine → brew → tumor
Adding it to a standard post-surgery treatment reduced by 42% the risk of melanoma returning two years after surgery, according to the most advanced study to date of this new strategy for fighting cancer. uncertain
melanoma → add → cancer
“The field has been looking for a win and I think this one is a big one,” said Dr. Hussein Tawbi of MD Anderson Cancer Center in Houston, one of the researchers in the international study. asserted
Tawbi → look → study
The vaccine, called intismeran, is made with the same Nobel Prize-winning mRNA technology that was behind COVID-19 vaccines. asserted
that → call → vaccines
Experimental personalized cancer vaccines made with mRNA and some other approaches also are being tested against other types of cancer including lung, kidney and pancreatic. asserted
vaccines → make → lung
Experts not involved with the new study say its success bolsters the field. asserted
success → involve → field
“This is a new frontier,” said Karen Knudsen, CEO of the Parker Institute, which helps fund cancer immunotherapy research. asserted
which → say → research
“It’s a big step forward for science, for oncology, because this vaccine will apply to many different cancers,” said Dr. Michael Atkins, deputy director of Georgetown University’s Lombardi Comprehensive Cancer Center. asserted
Atkins → ’ → Center
Moderna and Merck had announced in August that the late-stage trial of intismeran was successful but the detailed results were set to be released Saturday at a meeting of the European Society of Medical Oncology in Madrid. asserted
results → announce → Madrid
Some of the data was leaked publicly late Thursday, prompting a full release ahead of the weekend’s scientific presentation. asserted
Some → leak → presentation
Most people think of vaccines as preventing an infection, like measles or whooping cough. asserted
people → think → measles
There are already two cancer-preventing vaccines, the HPV and hepatitis B shots that block infection from those tumor-causing viruses. asserted
that → be → viruses
And research is underway to prevent some types of inherited cancer such as Lynch syndrome-caused colorectal cancer. asserted
research → prevent → cancer
But a personalized vaccine designed to block surgically-removed cancer from returning is very different. asserted
vaccine → design → cancer
For the intismeran study, scientists hunted gene mutations unique to each patient’s tumor, mutations that create proteins which shouldn’t be in the body unless those cancer cells start to grow again. asserted
cells → hunt → body
The custom vaccine — nine doses given three weeks apart — teaches the patient’s immune system to watch out for and attack those so-called neoantigens. asserted
vaccine → give → neoantigens
How did it work? asserted
it → work → ?
The study included more than 1,100 people with high-risk melanoma that was surgically removed. asserted
that → include → melanoma
Everyone was given the standard follow-up therapy: Merck’s immunotherapy named Keytruda. asserted
Everyone → give → therapy
The participants were randomly assigned to also receive custom-brewed vaccine doses or a placebo. asserted
participants → assign → doses
Two years later, 82% of the people in the vaccine group were still living without a recurrence of their cancer compared to 70% who had gotten standard Keytruda alone. asserted
who → live → Keytruda
The trial is continuing to track participants’ longer-term outcomes. asserted
trial → continue → outcomes
In 2024, Tony Hout joined the vaccine trial at MD Anderson after seeking care for a spot on his ear that had been bleeding intermittently and wouldn’t fully heal. asserted
that → join → ear
Doctors recognized melanoma and during surgery discovered it had started to spread. asserted
it → recognize → surgery
“I want to make sure I’m doing everything I can to be here for my family,” said Hout, 62, who has since moved to Cayuga, Indiana, and travels back to Houston every few months for a study check-up. asserted
who → want → up
Scans this week showed he’s still cancer-free. asserted
he → show → ?
The vaccine’s side effects were mainly the sore arm, fatigue and other reactions typical of mRNA coronavirus vaccination, MD Anderson’s Tawbi said. asserted
Tawbi → say → vaccination
Moderna and Merck are talking with regulatory authorities about next steps for seeking approval of the vaccine. asserted
Moderna → talk → vaccine
The drugmakers aren’t discussing what such a cancer vaccine might cost. uncertain
vaccine → discuss → what
But Moderna President Stephen Hoge said the company’s special cancer vaccine manufacturing facility in Massachusetts is providing doses for thousands of people enrolled in multiple studies underway internationally. asserted
facility → say → studies
Hoge said it takes a few days to brew the vaccine but the whole process, starting with analyzing the tumor genetics to come up with what is essentially a recipe for each patient, can take roughly six weeks, sometimes more. asserted
what → say → weeks
Meanwhile, the melanoma patients had already started their standard Keytruda, a different kind of immunotherapy. asserted
patients → start → immunotherapy
Moderna shares dropped 18% Thursday after the study’s full results were made public, but they remained more than 200% higher than they were in late August before investors were first told of the initial results. asserted
investors → drop → results
The Associated Press’ health and science coverage receives financial support from the AP Fund for Journalism and private foundations. asserted
coverage → receive → Journalism
Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

History Support